Kestra Medical Technologies Ltd.
KMTS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KMTS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KMTS
Kestra Medical Technologies Ltd. (KMTS) is a commercial-stage medical device company focused on its Cardiac Recovery System platform, including the ASSURE Wearable Cardioverter Defibrillator (WCD), with a history of net losses and an accumulated deficit of $446.7 million as of October 31, 2024 [sec].
Key risk: History of net losses
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$1.50B
Cash Runway
—
Lead Asset
assure wcd (Approved)
Next Catalyst
—
Financial data as of Apr 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Kestra Medical Technologies Ltd..
Kestra Medical Technologies Ltd. (KMTS) is a commercial-stage medical device company focused on its Cardiac Recovery System platform, including the ASSURE Wearable Cardioverter Defibrillator (WCD), with a history of net losses and an accumulated deficit of $446.7 million as of October 31, 2024 [sec].
- Kestra Medical Technologies has devoted substantially all efforts to research, clinical trials, manufacturing, and building a commercial team for its Cardiac Recovery System platform in the United States [sec_mda · as of 2026-03-17].
- As of October 31, 2024, the company had cash and cash equivalents of $76.9 million and an accumulated deficit of $446.7 million [sec · filed 2025-02-10].
- The company reported cash and cash equivalents of $201.2 million (actual) as of July 31, 2025, with long-term debt of $41.5 million [sec · filed 2025-12-01].
- Kestra believes its existing cash and cash equivalents, plus cash generated from revenue transactions, will fund operations for at least the next 12 months based on its current operating plan [sec_mda · as of 2026-03-17].
What works
- The company has established quality systems that meet FDA requirements for its ASSURE WCD and believes its manufacturers have sufficient capacity to scale for anticipated demand [sec_mda · as of 2026-03-17].
- Kestra is building and expanding a commercial team to market its Cardiac Recovery System platform in the United States, indicating a focus on revenue generation [sec_mda · as of 2026-03-17].
What to weigh
- Kestra has a history of net losses and an accumulated deficit of $446.7 million as of October 31, 2024, with no assurance of when profitability may be achieved [sec · filed 2025-12-01].
- The company faces risks related to obtaining and maintaining coverage and adequate reimbursement from governmental authorities and health insurers, which could limit its ability to market products profitably [sec_mda · as of 2025-07-17].
- Kestra may require additional funding to execute growth plans, and adequate financing may not be available on acceptable terms, which could adversely affect its business [sec_mda · as of 2026-03-17].
From the filings
Quoted directly from source documents.
Kestra has a history of net losses and an accumulated deficit.
“we have a history of net losses, and there is no assurance as to when we will achieve profitability, if at”
SEC filings · December 1, 2025
The company had cash and cash equivalents of $76.9 million and an accumulated deficit of $446.7 million as of October 31, 2024.
“As of October 31, 2024, we had cash and cash equivalents balances of $76.9 million, and an accumulated deficit of $446.7 million.”
SEC filings · February 10, 2025
Kestra believes its cash and cash equivalents will fund operations for at least the next 12 months.
“Based on our current operating plan, we believe that our existing cash and cash equivalents and cash generated from revenue transactions with customers will be sufficient to fund our operating and capital needs for at least the next 12 months.”
SEC MD&A · March 17, 2026
Risks & what to watch (4)›
Key risks
- History of net losses — Kestra has a history of net losses and an accumulated deficit of $446.7M as of Oct 2024, with no profitability assurance [sec · filed 2025-12-01].
- Reimbursement and adoption risks — Commercial success depends on coverage and adequate reimbursement from health insurers; failure could limit marketability [sec_mda · as of 2025-07-17].
- Need for additional funding — May require future equity or debt financing; adequate funds may not be available on acceptable terms [sec_mda · as of 2026-03-17].
- Clinical trial uncertainties — Clinical study initiatives are complex, lengthy, expensive, and carry uncertain outcomes [sec · filed 2025-12-01].
What to watch
- Progress in commercial adoption of the Cardiac Recovery System platform and revenue growth from customer transactions [sec_mda · as of 2026-03-17].
- Ability to obtain and maintain favorable reimbursement coverage from governmental and private payers [sec_mda · as of 2025-07-17].
- Cash runway and any need for additional financing, given the accumulated deficit and operating losses [sec_mda · as of 2026-03-17].
- Outcomes of ongoing or future clinical trials, which could affect regulatory and market positions [sec · filed 2025-12-01].
Sources: SEC filings · SEC MD&A · Generated August 23, 2026 · How we verify sources →
Run Kestra Medical Technologies Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kestra Medical Technologies Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
1 candidate
No upcoming catalysts tracked
1 buy · 33 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
102
Total value held
$1.03B
| Holder | Shares | Value |
|---|---|---|
| bain capital investors llc | 25,172,338 | $501.7M |
| fmr llc | 5,721,054 | $114.0M |
| andera partners | 2,695,192 | $53.7M |
| vanguard capital management llc | 2,425,386 | $48.3M |
| alliancebernstein l.p. | 1,320,374 | $35.0M |
| brown advisory inc | 1,723,730 | $34.4M |
| blackrock, inc. | 1,689,247 | $33.7M |
| eventide asset management, llc | 1,445,864 | $28.8M |
| franklin resources inc | 1,243,205 | $24.8M |
| omega fund management, llc | 1,022,149 | $20.4M |
Showing top 10 of 102 institutional holders of Kestra Medical Technologies Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 11, 2026- % of float
- 11.8%
- Days to cover
- 7.9
- Shares short
- 3,630,874
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KMTS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Kestra Medical Technologies Ltd.?
Kestra Medical Technologies Ltd. (KMTS) is a commercial-stage medical device company focused on its Cardiac Recovery System platform, including the ASSURE Wearable Cardioverter Defibrillator (WCD), with a history of net losses and an accumulated deficit of $446.7 million as of October 31, 2024 [sec].
What is Kestra Medical Technologies Ltd.'s lead drug candidate?
Kestra Medical Technologies Ltd.'s most advanced tracked candidate is assure wcd (Approved) for Cardiac Recovery System.
Who is the CEO of Kestra Medical Technologies Ltd.?
Mr. Brian Webster is the chief executive officer of Kestra Medical Technologies Ltd. (KMTS).
Where is Kestra Medical Technologies Ltd. headquartered?
Kestra Medical Technologies Ltd. (KMTS) is headquartered in Kirkland, WA, United States.
What therapeutic areas does Kestra Medical Technologies Ltd. focus on?
Kestra Medical Technologies Ltd. develops therapies across Oncology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.